Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Antibe Therapeutics Inc. has undergone significant changes, with the appointment of FTI Consulting Canada Inc. as receiver following the termination of its CCAA proceedings, and the resignation of five board members. Additionally, the company’s common shares are set to be delisted from the TSX on May 24, 2024.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.